Andel Launches New Direct-to-Employer Medication Platform to Make GLP-1s Affordable

Andel announced the launch of its app and medication platform, giving companies a new way to make GLP-1s an accessible employee benefit. The company is excited to announce that Eli Lilly and Company's newly-approved Zepbound^® KwikPen^® will be the inaugural medication available on the Andel platform.

Andel offers a unique cooperative model that leverages the combined power of its network to access medications directly from pharmaceutical manufacturers at lower costs. Employers then choose a contribution amount to lower out-of-pocket costs for their employees. Andel's solution does not require the use of a PBM, TPA, or insurance, helping create new pathways for employers to offer lower-cost brand name medications as competitive workplace benefits.

"More and more employees are clamoring for access to these medications, but companies need a fiscally responsible way to offer them," said Jay Bregman, founder and CEO of Andel. "Andel's platform aligns employers, workers, and pharmaceutical manufacturers as Americans continue to seek out affordable brand name medications.